Richard Scott Struthers Crinetics Pharmaceuticals, Inc. (CRNX) insider trading activity

CRNX Quotes by TradingView

Richard Scott Struthers is President & CEO of Crinetics Pharmaceuticals, Inc.. Currently has a direct ownership of 329,147 shares of CRNX, which is worth approximately $11 Million. The most recent transaction as insider was on Mar 19, 2025, when has been sold 17,338 shares (Common Stock) at a price of $34.5 per share, resulting in proceeds of $598,161. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 329K
27.83% 3M change
38.39% 12M change
Total Value Held $11 Million

Richard Scott Struthers Transaction History

Date Transaction Value Shares Traded Shares Held Form
Mar 19 2025
SELL
Open market or private sale
$598,161 $34.5 p/Share
17,338 Reduced 5.0%
329,147 Common Stock
Feb 20 2025
BUY
Grant, award, or other acquisition
-
89,000 Added 20.44%
346,485 Common Stock
May 08 2024
SELL
Open market or private sale
$5,307,931 $49.4 p/Share
107,448 Reduced 29.44%
257,485 Common Stock
May 08 2024
BUY
Exercise of conversion of derivative security
$997,117 $9.28 p/Share
107,448 Added 22.75%
364,933 Common Stock
Apr 18 2024
SELL
Bona fide gift
-
350 Reduced 0.14%
257,485 Common Stock
Apr 15 2024
BUY
Exercise of conversion of derivative security
$38,200 $1.91 p/Share
20,000 Added 7.2%
257,835 Common Stock
Apr 04 2024
SELL
Open market or private sale
$2,013,560 $49.17 p/Share
40,951 Reduced 14.69%
237,835 Common Stock
Apr 04 2024
BUY
Exercise of conversion of derivative security
$380,025 $9.28 p/Share
40,951 Added 12.81%
278,786 Common Stock
Mar 18 2024
SELL
Payment of exercise price or tax liability
$483,882 $38.14 p/Share
12,687 Reduced 5.06%
237,835 Common Stock
Mar 04 2024
BUY
Grant, award, or other acquisition
-
65,000 Added 20.6%
250,522 Common Stock
Nov 09 2023
BUY
Exercise of conversion of derivative security
$95,500 $1.91 p/Share
50,000 Added 21.23%
185,522 Common Stock
Nov 03 2023
SELL
Open market or private sale
$6,083,945 $30.56 p/Share
199,082 Reduced 59.5%
135,522 Common Stock
Nov 03 2023
BUY
Exercise of conversion of derivative security
$1,847,480 $9.28 p/Share
199,082 Added 37.3%
334,604 Common Stock
Nov 02 2023
SELL
Open market or private sale
$27,494 $29.95 p/Share
918 Reduced 0.67%
135,522 Common Stock
Nov 02 2023
BUY
Exercise of conversion of derivative security
$8,519 $9.28 p/Share
918 Added 0.67%
136,440 Common Stock
Aug 14 2023
BUY
Exercise of conversion of derivative security
$19,100 $1.91 p/Share
10,000 Added 6.87%
135,522 Common Stock
Mar 16 2023
SELL
Payment of exercise price or tax liability
$79,231 $17.12 p/Share
4,628 Reduced 3.56%
125,522 Common Stock
Mar 01 2023
BUY
Grant, award, or other acquisition
-
61,650 Added 32.14%
130,150 Common Stock
Oct 12 2022
BUY
Exercise of conversion of derivative security
$21,201 $1.91 p/Share
11,100 Added 13.94%
68,500 Common Stock
Feb 28 2022
BUY
Grant, award, or other acquisition
-
53,400 Added 48.19%
57,400 Common Stock
Dec 03 2020
BUY
Open market or private purchase
$52,400 $13.1 p/Share
4,000 Added 50.0%
4,000 Common Stock
May 08 2019
SELL
Bona fide gift
-
1,215,805 Reduced 100.0%
0 Common Stock
RSS

Richard Scott Struthers

President & CEO
San Diego, CA

Track Institutional and Insider Activities on CRNX

Follow Crinetics Pharmaceuticals, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CRNX shares.

Notify only if

Insider Trading

Get notified when an Crinetics Pharmaceuticals, Inc. insider buys or sells CRNX shares.

Notify only if

News

Receive news related to Crinetics Pharmaceuticals, Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on CRNX